Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBT (2016 - 2025)

Sangamo Therapeutics has reported EBT over the past 16 years, most recently at -$38.0 million for Q4 2025.

  • Quarterly results put EBT at -$38.0 million for Q4 2025, down 59.39% from a year ago — trailing twelve months through Dec 2025 was -$123.5 million (down 25.88% YoY), and the annual figure for FY2025 was -$123.5 million, down 25.88%.
  • EBT for Q4 2025 was -$38.0 million at Sangamo Therapeutics, down from -$35.1 million in the prior quarter.
  • Over the last five years, EBT for SGMO hit a ceiling of $21.3 million in Q1 2023 and a floor of -$120.8 million in Q2 2023.
  • Median EBT over the past 5 years was -$43.5 million (2022), compared with a mean of -$42.7 million.
  • Biggest five-year swings in EBT: crashed 3645.24% in 2021 and later soared 148.56% in 2023.
  • Sangamo Therapeutics' EBT stood at -$37.6 million in 2021, then plummeted by 37.67% to -$51.7 million in 2022, then decreased by 17.12% to -$60.6 million in 2023, then skyrocketed by 60.67% to -$23.8 million in 2024, then crashed by 59.39% to -$38.0 million in 2025.
  • The last three reported values for EBT were -$38.0 million (Q4 2025), -$35.1 million (Q3 2025), and -$20.0 million (Q2 2025) per Business Quant data.